Navigation Links
Proacta Incorporated Announces IND Allowance for PR610
Date:8/29/2012

SAN DIEGO, Aug 29, 2012 /PRNewswire/ -- Proacta Incorporated announced today that the US Food and Drug Administration has allowed its Investigational New Drug (IND) Application for PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer.

The IND allowance permits Proacta to initiate human clinical trials of this novel, first in class treatment. Initially, development will focus on patients with non-small cell lung cancer who have developed resistance to reversible tyrosine kinase inhibitors such as erlotinib and /or gefitinib. In such cases, no effective treatment is currently available.

The first clinical study will be conducted at sites in the US and New Zealand. Proacta expects to initiate patient enrollment in the coming weeks.

About PR610

PR610 is Proacta's proprietary hypoxia-activated irreversible MKI discovered at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. Reversible MKI's are currently used for the treatment of several types of cancer. However, resistance often develops to reversible MKI's and side effects limit their use at higher doses.

PR610 utilizes an irreversible MKI that is activated in areas of severe hypoxia, a characteristic of most solid tumors. Localized release of the irreversible MKI within tumors leads to higher tumor concentrations and lower concentrations in normal tissues, which should result in improved efficacy and fewer side effects. In addition, irreversible MKI inhibitors are not affected by some of the resistance mechanisms that limit use of reversible MKI inhibitors.

In subsequent studies, Proacta expects to evaluate PR610 in other cancers that are currently treated with first-generation reversible tyrosine kinase inhibitors such as gastric, breast, and pancreatic.

In 2011, Proacta engaged in the collaboration for research, development and commercialization of PR610 in Japan with Yakult Honsha Co., Ltd
'/>"/>

SOURCE Proacta
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Accuray Incorporateds CEO to Speak at Morgan Stanley Global Healthcare Conference
2. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
3. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
4. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
5. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
6. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
7. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
8. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
9. Tribogenics Announces Dual-Energy X-ray Source for XRF
10. Eaton Scientific Announces Clinical Trial Plans for Tropine 3 - Company to Seek FDA Approval as Novel Prescription Drug for Non-Hormonal Treatment of Hot Flashes in Menopausal Women
11. Cynosure Announces Upcoming Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Germany , and MARSEILLE, ... , Exclusive global license from University ... mutations, including next-generation sequencing (NGS) gene panels, for blood ... targeted by new test, indicate favorable prognosis for patients ... QIAGEN sees potential for developing companion diagnostics to ...
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
(Date:7/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... announced its financial results for the second quarter ended June ... , Total revenues of $6.5 million in the second quarter ... in 2013 , Total revenues of $13.3 million for ... 78% over the same period in 2013 , Total ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... New "Oxygen Sandwich" Device is First to Mimic Natural ... the major challenges to islet,cell transplantation as the treatment ... donor tissue supply. Patients often need a re-infusion of ... donor pancreas is,needed to provide the fragile islet cells ...
... Ozarelix Was Maintained For ... Up To Six Months, ... IRVINE, Calif., Sept. 5 Spectrum,Pharmaceuticals, Inc., (Nasdaq: SPPI ) ... drug candidate for the,treatment of benign prostatic hypertrophy (BPH), at the 29th ...
Cached Medicine Technology:Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 3Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 4Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 5
(Date:7/25/2014)... As reported by the Statesman Journal in the ... (7/20), police in Salem, MA as well as several other ... heroin epidemic that has taken many lives during the past ... case in which police were able to make two arrests ... pretending to be the victim and claiming to want to ...
(Date:7/25/2014)... (HealthDay News) -- Seniors are more easily distracted during ... study finds. "Almost any type of memory test ... of 25 on," study co-author Randi Martin, professor of ... release. However, Martin said, this study shows that ... older adults compared with younger adults. The study ...
(Date:7/25/2014)... 25, 2014 Reproductive Science Center (RSC) ... Dr. Kerri Luzzo, Lead Physician at RSC Rhode Island, ... professional accomplishments in fertility care and community outreach issued ... 10th Annual PBN Awards ceremony held July 24th at ... the most highly regarded, emerging leaders in their field ...
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- The human brain ... of dehydration, a new study finds. Although ... in England have found that the brain compensates by ... blood. "This research has helped us understand a ... extreme exercise in extreme conditions," study first author Steven ...
(Date:7/25/2014)... York, ON (PRWEB) July 25, 2014 A ... Michael’s Hospital revealed that 39 percent of all children in ... a dentist. , The survey looked at 2,505 children during the ... all around four years of age. The final result was ... any dental care. Many of these children were from lower-income families ...
Breaking Medicine News(10 mins):Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Distractions Seem More Troublesome With Age 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3
... Effect Sept. 11; Online Resources and Helpline Now,Available, ... date of Pennsylvania,s Clean Indoor Air Act fast approaching, ... to help,them comply with the law that will ban ... portion of casino floors., Guidance and a downloadable ...
... MBF Healthcare,Acquisition Corp. (Amex: MBH ), ... today the amendment of the Stock Purchase,Agreement ... Solutions,Holdings, Inc. ("CHS"), based on the signed ... (the "Stock Purchase Agreement"). CHS is a,privately-owned, ...
... 2 Ethiopia,s Ministry of Health,recently signed a ... at helping the country reach the U.N.,s Millennium,Development ... do so., The agreement provides a framework ... Ethiopia and the partners who are,contributing to the ...
... even a year after routine was stopped, study says ... may help treat memory problems in adults, according to ... 138 people age 50 and older at increased risk ... led to modest improvements in cognitive function in adults ...
... benefit of nation,s 1st such law, passed in 2004 , , ... ill kids have made use of California,s pioneering paid family ... it exists, according to researchers at the Rand Corp. ... law. It is funded by employees through an automatic payroll ...
... Normal Weight Obesity: A Real Health Risk, ... are,highlights from the September issue of Mayo ... as often as you wish. Mayo Clinic ... for a fee.,Include the following subscription information ...
Cached Medicine News:Health News:PA Department of Health Reminds Businesses to Prepare to Implement Clean Indoor Air Act 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 3Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 4Health News:Ethiopia First Nation to Sign National Health Partnership Compact 2Health News:Exercise May Help Prevent Age-Related Memory Loss 2Health News:Paid Family Leave Program Goes Mostly Unused 2Health News:September 2008 Mayo Clinic Women's HealthSource Highlights Normal Weight Obesity, Regular Exercise and Cholesterol 2Health News:September 2008 Mayo Clinic Women's HealthSource Highlights Normal Weight Obesity, Regular Exercise and Cholesterol 3Health News:September 2008 Mayo Clinic Women's HealthSource Highlights Normal Weight Obesity, Regular Exercise and Cholesterol 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: